指南与共识胸部肿瘤支持与姑息治疗

肺癌化疗指南与共识的质量评价

[Quality assessment of guidelines and consensus in lung cancer chemotherapy].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究检索多个数据库,纳入14篇肺癌化疗相关临床实践指南与共识,采用AGREE Ⅱ和RIGHT工具评价其质量与报告规范性。结果显示AGREE Ⅱ各领域平均分从43分到94分不等,7篇为A级、6篇B级、1篇C级;RIGHT评价显示多个领域存在不足,国内外指南规范性差距较大。结论认为整体质量较好但规范性有待加强。

要点

  • AGREE Ⅱ评价中严谨性平均得分最低为43分,范围和目的最高为94分。
  • 14篇指南中7篇推荐等级为A级,6篇为B级,1篇为C级。
  • RIGHT评价显示背景、证据、推荐意见等6个领域存在较多不足。

核心结论

  • 肺癌化疗相关临床指南与共识整体质量较好,但规范性有待加强。
  • 国内外指南质量和规范性存在较大差距。
  • 还需进一步制定高质量的临床实践指南,以及制定符合中国实际情况的适用性指南。

研究设计与样本

  • 检索Pubmed、EMbase、Cochrane图书馆、中国知网、万方数据库、中国生物医学文献数据库等数据库和相关网站。
  • 按照既定纳入排除标准筛选肺癌化疗相关的临床实践指南与共识。
  • 共纳入指南与共识14篇。
  • 使用AGREE Ⅱ和RIGHT工具对纳入指南共识的质量和报告规范程度进行评价。

主要发现

  • AGREE Ⅱ评价显示范围和目的平均得分为94分,参与人员平均得分为60分,严谨性平均得分为43分,清晰性平均得分为88分,应用性平均得分为50分,独立性平均得分为61分。
  • 7篇指南推荐等级为A级,6篇为B级,1篇为C级。
  • RIGHT评价显示纳入的指南共识在除基本信息外,背景、证据、推荐意见、评审和质量保证、资金资助与利益冲突声明和管理以及其他方面6个领域存在很多不足。
  • 国内外指南规范性差距较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To understand the current status of clinical guidelines and consensus for lung cancer chemotherapy, evaluate and analyze the quality of lung cancer chemotherapy treatment guidelines, and provide references for the revision and improvement of lung cancer chemotherapy clinical decision-making and guidelines. Methods: Search Pubmed, EMbase, Cochrane Library (Cochrane Library), China Knowledge Network, Wanfang Database, China Biomedical Literature Database and other related databases and clinical practice guidelines related to lung cancer chemotherapy, and screen the literatures according to the established inclusion exclusion criteria. Use the appraisal of guidelines for research and evaluation Ⅱ (AGREE Ⅱ) and reporting items for practice guidelines in healthcare (RIGHT) tools to compare and evaluate the quality of the included guides and the level of reporting specifications. Results: A total of 14 guidelines were included. The assessment results of AGREE Ⅱ showed that the average score of scope and purpose was 94 points, the average score of stakeholder involvement was 60 points, the average score of rigour of development was 43 points, the average score of clarity of presentation was 88 points, the average score of applicability was 50 points, the average score of editorial independence was 61 points. Seven guidelines were evaluated as A level, 6 guidelines were evaluated as B level, 1 guideline was evaluated as C level. The assessment results of RIGHT showed that, in addition to the basic information, the included guidelines have many deficiencies in 6 areas including background, evidence, recommendation, review and quality assurance, funding, declaration and management of interests and other information, and the normative gap between domestic and foreign guides was large. Conclusions: The overall quality of clinical guidelines for lung cancer chemotherapy is high, but the standardization needs to be strengthened. There is a big gap between the quality and standardization of domestic and foreign guides. Further developments of high-quality clinical practice guidelines and guidelines consistent with our country's actual situation are needed. 目的: 了解肺癌化疗临床指南与共识的现状,评价和分析其质量,为肺癌化疗临床决策和指南共识的修订和完善提供参考。 方法: 检索Pubmed、EMbase、Cochrane图书馆(Cochrane Library)、中国知网、万方数据库、中国生物医学文献数据库等数据库和相关网站与肺癌化疗相关的临床实践指南与共识,按照既定纳入排除标准筛选文献,使用临床实践指南研究与评价系统Ⅱ(AGREEⅡ)和实践指南报告标准工具(RIGHT)标准对纳入指南共识的质量和报告规范程度进行评价。 结果: 共纳入指南与共识14篇。AGREE Ⅱ质量评价结果显示,范围和目的平均得分为94分,参与人员平均得分为60分,严谨性平均得分为43分,清晰性平均得分为88分,应用性平均得分为50分,独立性平均得分为61分;7篇指南推荐等级为A级,6篇为B级,1篇为C级。RIGHT评价结果显示,纳入的指南共识在除基本信息外,背景、证据、推荐意见、评审和质量保证、资金资助与利益冲突声明和管理以及其他方面6个领域存在很多不足,且国内外指南规范性差距较大。 结论: 肺癌化疗相关临床指南与共识整体质量较好,但规范性有待加强;国内外指南质量和规范性存在较大差距;还需进一步制定高质量的临床实践指南,以及制定符合中国实际情况的适用性指南。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhou YP, Yang M, Yao PT, et al. [Quality assessment of guidelines and consensus in lung cancer chemotherapy]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 33342159. doi:10.3760/cma.j.cn112152-20190508-00293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。